FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma



Status:Not yet recruiting
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:3/1/2019
Start Date:June 1, 2019
End Date:October 1, 2024
Contact:Andrew Quon, MD
Email:aquon@mednet.ucla.edu
Phone:310-983-1438

Use our guide to learn which trials are right for you!

A research study of a new method of visualizing internal organs called 18F-FLT PET/CT that
yields better tracking of cancer treatment progress. PET/CT stands for positron emission
tomography with low dose computed tomography and has been used for many years. 18F-FLT PET/CT
uses a new tracer, fluorothymidine, which is taken up by cells that are actively
proliferating or dividing such as cancer cells. We hope to learn whether this tracer is
superior to the conventional tracer for monitoring treatment of diffuse large B-cell lymphoma
(DLBCL).

-Primary Objective

Investigate whether the PPV of FLT-PET/CT is significantly higher than that of FDG-PET/CT by
following up patients for at least 24 months post-therapy or until evidence of persistent
disease/disease progression.

-Secondary Objectives

Investigate whether the event free survival (EFS) of patients with FDG-PET/CT-positive and
FLT-PET/CT negative scans is not significantly lower than that of patients with concordantly
negative FDG-PET/CT and FLT-PET/CT scans and that the NPV or FLT-PET/CT is similar to that of
FDG-PET/CT

Correlate interim FLT-PET/CT and FDG-PET/CT with the International Prognostic Index (IPI), a
well-established predictor of outcome in DLBCL, to determine their independent prognostic
value from the IPI

Inclusion Criteria:

- All patients must have a histologic or cytological diagnosis of de novo DLBCL and be
scheduled to receive first line chemotherapy with R-CHOP given every 21 days
(R-CHOP-21) within 6 weeks of their enrollment and for 6 cycles.

- Patients must be >=18 years of age, but there will be no discrimination based on
gender, race, creed, or ethnic background.

- Patients must have an ECOG performance status of 0-2.

- Patients must sign an informed consent, and be mentally responsible.

Exclusion Criteria:

- Subjects with significant concurrent medical complications that in the judgment of the
Principal Investigator(s) could affect the patient's ability to complete the planned
trial, including the multiple imaging studies.

- Patients with history of prior lymphoma (e.g., follicular lymphoma) and/or second
cancers other than basal cell carcinoma.

- Patients planned to be treated with R-CHOP-14 (i.e., R-CHOP given every 14 days) will
be excluded (this should be extremely rare, if at all, since R-CHOP-21 is the standard
treatment.

- Patients who are scheduled to receive Rituxan or any other therapy (e.g., XRT,
radioimmunotherapy) as adjuvant therapy after completion of R-CHOP-21.

- Pregnant women will be excluded.

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) after study entry and for
the duration of study participation. The effects of FLT on the developing human fetus
are unknown. Should a woman become pregnant or suspect she is pregnant while
participating in this study, she should inform her treating physician immediately. A
screening urine human chorionic gonadtropin (hCG) (pregnancy test) will be
administered in Nuclear Medicine to women of childbearing potential before each FLT
scan and pregnant women will be stopped from participating further in this study.
We found this trial at
4
sites
Los Angeles, California 90095
310-825-4321
Principal Investigator: Andrew Quon, MD
Phone: 310-983-1438
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
55 Templergraben
Aachen, 52062
Principal Investigator: Malik Juweid, MD
Phone: 01149241-8 0 35905
?
mi
from
Aachen,
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
Emile St
Omaha, Nebraska 68198
(402) 559-4000
Principal Investigator: Jordan H Hankins, MD
Phone: 402-559-8155
Univ of Nebraska Med Ctr A vital enterprise in the nation’s heartland, the University of...
?
mi
from
Omaha, NE
Click here to add this to my saved trials